- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03059030
Yttrium-90 Radioembolization for Cirrhosis-Associated Thrombocytopenia
November 8, 2023 updated by: Riad Salem, Northwestern University
Evaluate the safety and efficacy of Yttrium-90 (90Y) radioembolization for the management of thrombocytopenia.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
This protocol will provide access to TheraSphere® treatment for patients who have refractory thrombocytopenia secondary to cirrhosis.
This protocol will utilize splenic artery-directed TheraSphere® treatment.
Study Type
Interventional
Enrollment (Estimated)
20
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Carlene del Castillo, RN
- Phone Number: 312-695-1518
- Email: carlene.castillo@northwestern.edu
Study Contact Backup
- Name: Riad Salem, MD MBA
- Phone Number: 312-695-6371
- Email: r-salem@northwestern.edu
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Recruiting
- Northwestern University/Northwestern Memorial Hospital
-
Contact:
- Carlene del Castillo, RN
- Phone Number: 312-695-1518
- Email: carlene.castillo@northwestern.edu
-
Contact:
- Riad Salem, MD MBA
- Phone Number: 312-695-6371
- Email: r-salem@northwestern.edu
-
Principal Investigator:
- Riad Salem, MD MBA
-
Sub-Investigator:
- Daniel Ganger, MD
-
Sub-Investigator:
- Laura Kulik, MD
-
Sub-Investigator:
- Young K Chae, MD
-
Sub-Investigator:
- John Hayes, MD
-
Sub-Investigator:
- Robert Lewandowski, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 99 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Male or female, 18 years of age or older, of any ethnic or racial group.
- Diagnosis of cirrhosis or portal hypertension with a serum platelet count less than or equal to 80 × 109/L. [Rationale: platelet count <100 × 109/L triples the rate of liver-related adverse events (3) and worsens postoperative survival in the setting of hepatocellular carcinoma (HCC) (4). Initial platelet count of 80 × 109/L can allow the majority of patients who successfully respond to 90Y-RE (clinical endpoint of 50% platelet count increase) to exceed the 100 × 109/L threshold.]
Cirrhosis is defined by one of three criteria:
- Liver Biopsy/histology consistent with cirrhotic architectural liver changes
- Portal hypertension (Hepatic venous pressure gradient ≥10 mm Hg)
- Evidence of esophageal and/or gastric varices
- Patients must have evidence of splenomegaly as determined by screening cross-sectional imaging.
- No evidence of myelosuppression (e.g. lymphopenia) as evidenced by normal hematology values at Screening
- Adequate baseline organ function(with the exception of cirrhosis) as evidenced by normal BUN/Cr and electrolytes on screening chemistry.
- Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0-2
- Patient has a life expectancy of greater than 6 months without intervention.
- Patient is willing to participate in the study and has signed the study informed consent.
- Women of childbearing potential must have a negative serum pregnancy test within 28 days prior to screening and must not be breastfeeding.
Exclusion Criteria:
- Patients with serum platelet count less than 10 × 109/L.
- History of bleeding disorder attributed to another cause other than cirrhosis (e.g. Von Willebrand disease)
- Declines or unable to provide informed consent
- History of prior partial splenic embolization (PSE) or splenectomy
- Use of any medication known to increase platelet count 1 month prior to Baseline.
- History of allergy or sensitivity to TheraSphere® or its components.
- History of severe peripheral allergy or intolerance to contrast agents, narcotics, sedatives or atropine that cannot be managed medically
- Contraindications to angiography and selective visceral catheterization such as bleeding, diathesis or coagulopathy that is not correctable by usual therapy or hemostatic agents (e.g. closure device)
- Previous randomization in a trial using 90Y RE
- Patient must not have participated or enrolled in a clinical trial with an investigational device / therapy within 30 days prior to randomization
- Any serious medical condition likely to impede successful completion of the study, such as certain mental disorders, cardiac arrhythmias, and uncontrolled congestive heart failure or respiratory disease.
- Patients actively on chemotherapy.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Subjects with thrombocytopenia secondary to cirrhosis
Evaluate the safety and efficacy of 90Y radioembolization for the management of thrombocytopenia.
|
The Interventional Radiologists will inject a dose of Yttrium 90 into your spleen through a small catheter placed in your femoral artery.The entire treatment visit is an outpatient procedure.
You will only be admitted to the hospital if the physician deems it necessary due to any symptoms you may experience after the treatment is given.
This visit may take 6 to 8 hours.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety of 90Y Radioembolization (RE) for the treatment of thrombocytopenia in the setting of cirrhosis, evaluated by the number of participants with treatment-related adverse events as assessed by CTCAE v4.0.
Time Frame: 6 months
|
Assess for infection after Y90 treatment to the spleen by physical exam noted by a change in vital signs and lab values such as white blood count at each follow up visit.
|
6 months
|
Safety of 90Y RE for the treatment of thrombocytopenia in the setting of cirrhosis.
Time Frame: 6 months
|
Assess for splenic abscess after Y90 to the spleen as seen on follow up CT imaging at 1, 3, and 6 months post treatment.
This will also be evaluated at all visits by physical exam, fever, pain, and lab work.
Visits occur at 2, 4, 6, 8 weeks, 3, 4, 5, 6 months.
|
6 months
|
Safety of 90Y RE for the treatment of thrombocytopenia in the setting of cirrhosis.
Time Frame: 6 months
|
Assess for any adverse events after Y90 administration at follow visits or outside visits if they occur by physical exam and lab values at baseline, 2, 4, 6, 8 weeks, 3, 4, 5, 6 months post treatment.
Lab value changes, ascites, fatigue, fever, nausea, dyspepsia, abdominal pain, pleural effusion, GI ulcer, pneumonitis, and thromboembolic events will be followed closely.
|
6 months
|
Asses the need for Technetium albumin aggregated (TC-MAA 99m) injection to determine shunting prior to Y90 administration
Time Frame: 6 months
|
MAA injection will be done and nuclear medicine PET scan to evaluate shunting and evaluated for the first 5 patients.
If shunt is <5% subsequently enrolled patients will not undergo MAA, if shunt is >5% all subsequent patients will undergo MAA.
This will be evaluated post MAA injection before Y90 treatment.
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluate platelet count 6 months after treatment
Time Frame: 6 months
|
Complete Blood Count with platelets will be drawn at baseline, treatment, 2, 4, 6, 8 weeks and 3, 4, 5, 6 months post treatment
|
6 months
|
Evaluate splenic volume post procedure
Time Frame: 6 months
|
CT or MR of the abdomen will be done at screening, 4 weeks, 3 months, and 6 months after Y90 administration
|
6 months
|
Evaluate length of hospital stay after procedure
Time Frame: 6 months
|
Length of stay in days will be recorded post procedure
|
6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Riad Salme, MD, Northwestern University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 16, 2017
Primary Completion (Estimated)
April 1, 2025
Study Completion (Estimated)
April 1, 2025
Study Registration Dates
First Submitted
February 8, 2017
First Submitted That Met QC Criteria
February 20, 2017
First Posted (Actual)
February 23, 2017
Study Record Updates
Last Update Posted (Estimated)
November 9, 2023
Last Update Submitted That Met QC Criteria
November 8, 2023
Last Verified
November 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- STU 00203772
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Thrombocytopenia
-
Weill Medical College of Cornell UniversityColumbia University; New York Presbyterian HospitalCompletedAlloimmune Thrombocytopenia | Fetal Alloimmune ThrombocytopeniaUnited States
-
Sylvia ElzekUnknownThrombocytopenia Neonatal
-
Central Hospital, Nancy, FranceRecruitingHeparin-induced ThrombocytopeniaFrance
-
Centre Hospitalier Universitaire de BesanconNot yet recruitingHeparin-induced Thrombocytopenia
-
University of ArizonaAmerican College of Clinical PharmacyRecruitingHeparin-induced ThrombocytopeniaUnited States
-
Veralox TherapeuticsCelerionCompletedHeparin-induced ThrombocytopeniaUnited States
-
Aspen Global IncorporatedTerminatedHeparin-induced ThrombocytopeniaUnited States, Bosnia and Herzegovina, Canada, France, Germany, Italy, Poland, Russian Federation, Serbia
-
Marshall UniversityUnknownHeparin-induced ThrombocytopeniaUnited States
-
Ottawa Hospital Research InstituteUnknownHeparin-induced Thrombocytopenia (HIT)Canada
-
Napolitano MariasantaRegione SiciliaTerminatedThrombocytopenia | Primary Thrombocytopenia,Unspecified | Thrombocytopenia Chemotherapy InducedItaly
Clinical Trials on TheraSphere® Yttrium-90 Glass Microspheres, BTG International Inc.
-
Boston Scientific CorporationRecruitingCancer | ProstateUnited States
-
H. Lee Moffitt Cancer Center and Research InstituteBTG International Inc.CompletedCholangiocarcinomaUnited States
-
Boston Scientific CorporationBTG International Inc.CompletedNeoplasm Metastasis | Colorectal Cancer | Carcinoma, NeuroendocrineUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedUnresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | Stage IIIB Hepatocellular Carcinoma...United States
-
Boston Scientific CorporationBiocompatibles UK LtdActive, not recruiting
-
Yale UniversityCompletedLiver NeoplasmsUnited States
-
Southwestern Regional Medical CenterCompletedCarcinoma, Hepatocellular | Liver NeoplasmsUnited States
-
Leo W. Jenkins Cancer CenterNo longer availableNeoplasm Metastasis | Carcinoma, HepatocellularUnited States
-
Boston Scientific CorporationRecruitingGlioblastoma Multiforme | Recurrent GlioblastomaUnited States
-
Ohio State University Comprehensive Cancer CenterCompletedAdvanced Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Recurrent Adult Primary Liver Cancer | Adult Primary Hepatocellular CarcinomaUnited States